Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $15.40.

A number of analysts have issued reports on ANRO shares. William Blair reissued an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. HC Wainwright initiated coverage on Alto Neuroscience in a research note on Monday, April 7th. They set a "buy" rating and a $10.00 price target for the company.

Hedge Funds Weigh In On Alto Neuroscience

A number of large investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in Alto Neuroscience in the 4th quarter worth approximately $3,542,000. Point72 Asset Management L.P. increased its holdings in shares of Alto Neuroscience by 73.1% in the fourth quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company's stock worth $7,158,000 after purchasing an additional 714,461 shares during the period. Franklin Resources Inc. increased its holdings in shares of Alto Neuroscience by 95.3% in the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company's stock worth $13,965,000 after purchasing an additional 595,673 shares during the period. Woodline Partners LP raised its position in shares of Alto Neuroscience by 397.6% in the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company's stock worth $2,631,000 after buying an additional 496,976 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Alto Neuroscience by 198.1% during the fourth quarter. Northern Trust Corp now owns 587,135 shares of the company's stock valued at $2,484,000 after buying an additional 390,190 shares during the period.

Alto Neuroscience Stock Performance

Alto Neuroscience stock traded down $0.01 during mid-day trading on Tuesday, reaching $2.25. 148,826 shares of the company's stock were exchanged, compared to its average volume of 374,856. The firm has a market capitalization of $60.78 million, a PE ratio of -0.88 and a beta of 2.16. Alto Neuroscience has a one year low of $1.60 and a one year high of $17.55. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The business's fifty day simple moving average is $2.74 and its 200 day simple moving average is $4.63.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.09. On average, sell-side analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.